Freeline Therapeutics soars as FDA clears new drug application

Freeline Therapeutics Holdings

06/01/2022 12:15

** Drug developer's shares  FRLN.O  up 19% at $2.34
premarket 
    ** Says U.S. Food and Drug Administration has cleared its
Investigational New Drug application for FLT201 as a gene
therapy to treat Gaucher disease Type 1  urn:newsml:reuters.com:*:nGNX2h6VgF
    ** Co has started an early-stage dose-finding trial at the
end of 2021 in Europe and expects to dose two patients in the
first dose cohort in the first half of 2022 
    ** Gaucher disease is a genetic disorder that usually
impacts the spleen, liver, blood system and bones
    ** Stock down 89% for the last 12 months, up to Wed close

 (Reporting by Ankur Banerjee in Bengaluru)